FDA warned www.portmeds.com for selling unapproved, misbranded opioids, benzodiazepines, and Schedule II stimulants online without prescriptions.
What happened
FDA reviewed the website www.portmeds.com and found it offering unapproved and misbranded opioids, benzodiazepines, and Schedule II stimulants to U.S. consumers, plus prescription drugs without a prescription. The letter says website claims show the products are drugs intended for human use, but no FDA-approved applications are in effect for the named products. No inspection was stated; FDA found the issues through its website review.
What FDA found
The website offered opioids, benzodiazepines, and Schedule II stimulants that are new drugs without FDA-approved applications.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]The website's drug labeling did not include adequate directions for safe use by a layperson, so FDA calls the drugs misbranded.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]; section 301(a) [21 U.S.C. § 331(a)]The website offered prescription drugs, including Percocet, for sale without requiring a prescription.
FD&C Act sections 503(b)(1) and 301(k) [21 U.S.C. §§ 353(b)(1), 331(k)]The website marketed specific opioid products such as tapentadol, hydrocodone, oxycodone, and tramadol under labels FDA has not approved.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]
What FDA wants
FDA asks www.portmeds.com to stop offering unapproved and misbranded drugs to U.S. consumers and to reply in writing within 15 working days with the specific steps taken and supporting documents.
Who should pay attention
- consumers who buy prescription drugs online
- online pharmacy operators and affiliates
- platforms and payment or shipping partners that serve drug websites
This is a summary. Read the original letter on fda.gov.